Boston Scientific's Corporate Warning Letter Completely Lifted

FDA has removed all remaining aspects of the "corporate warning letter" Boston Scientific received in January 2006 that had prevented it from bringing new products to market, CEO James Tobin said in a conference call with analysts. The measure was imposed in reaction to rampant manufacturing violations. Parts of it have been lifted in the past year, but now all of it is gone, reports Bloomberg News.

October 23, 2008

1 Min Read
Boston Scientific's Corporate Warning Letter Completely Lifted

Tobin said the move will allow the firm to introduce stents to treat blockages in the carotid artery and kidney, as well as a balloon catheter for unclogging blood vessels. Its newest heart stent, Taxus Liberte, was approved Oct. 10 after some of the restrictions were lifted.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like